Breaking Finance News

Vectura Group PLC (LON:VEC) target price held steady at 160.00GBX, reported today by Peel Hunt

Vectura Group PLC (LON:VEC) had its target price hold steady to 160.00GBX by Peel Hunt in a report released 11/14/2017. The new target price indicates a possible upside of 0.77% based on the company's last stock close price.

Previously on 11/10/2017, JP Morgan Cazenove reported about Vectura Group PLC (LON:VEC) lowered the target price from 180.00GBX to 175.00GBX. At the time, this indicated a possible upside of 0.95%.

Yesterday Vectura Group PLC (LON:VEC) traded 3.27% higher at 90.48GBX. The company’s 50-day moving average is 102.39GBX and its 200-day moving average is 114.70GBX. The last stock close price is down -11.77% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 1,114,830 shares of the stock were exchanged, down from an average trading volume of 1,633,170

See Chart Below

Vectura Group PLC (LON:VEC)

Vectura Group PLC has a 52 week low of 88.90GBX and a 52 week high of 166.97GBX VEC’s total market value is presently 0 GBX.

A total of 6 brokerages have issued a ratings update on VEC. Four equity analysts rating the stock a strong buy, 2 firms rating the stock a buy, 1 firm rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of 215.67GBX.

General Information About Vectura Group PLC (LON:VEC)

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *